Related Experiment Videos
Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: an update
Insights
Bone marrow transplants offer a promising treatment for acute nonlymphoblastic leukemia in children. This study shows a 64% disease-free survival rate, with most survivors leading normal lives post-transplant.
Area of Science:
- Pediatric Oncology
- Hematology
- Transplantation Immunology
Background:
- Acute nonlymphoblastic leukemia (ANLL) is a significant pediatric cancer.
- Chemotherapy-induced remission is a critical step before further treatment.
- Hematopoietic stem cell transplantation (HSCT) is a potential curative option for relapsed or refractory leukemia.
Purpose of the Study:
- To evaluate the efficacy and long-term outcomes of allogeneic bone marrow transplantation (BMT) in children with ANLL in first remission.
- To assess survival rates, relapse incidence, and quality of life after BMT.
Main Methods:
- Thirty-eight pediatric patients (0.8-17 years) with ANLL in first remission received cyclophosphamide, total body irradiation, and HLA-matched sibling bone marrow transplants.
- Patient outcomes were monitored for disease recurrence, survival, and complications.
Main Results:
- Twenty-five patients (66%) achieved continuous remission, with survival ranging from 1.7 to 8.4 years post-transplant.
- The actuarial disease-free survival rate was 64%, with a plateau observed from 3.5 to 8.4 years.
- Mortality was primarily due to infections (n=6) and graft-versus-host disease complications (n=1). Five patients relapsed, with three succumbing to leukemia.
Conclusions:
- Allogeneic bone marrow transplantation is an effective treatment for pediatric acute nonlymphoblastic leukemia, offering a high chance of long-term disease-free survival.
- Survivors generally lead normal lives, indicating a favorable quality of life post-treatment.
- Careful management of post-transplant complications, such as infections and graft-versus-host disease, is crucial for improving outcomes.
Abstract:
Thirty-eight children between the ages of 0.8 and 17 years with acute nonlymphoblastic leukemia in first remission induced by chemotherapy were given cyclophosphamide, total body irradiation, and bone marrow transplants from HLA-matched donors. Six patients died of pneumonia, one died of metabolic problems, and one died of chronic graft-v-host disease complications. Five patients relapsed between six months and 3.2 years after transplantation. Three of the five died of leukemia, one survives with leukemia three years after transplantation, and one survives in remission off treatment following chemotherapy for 22 months. Twenty-five survive in continuous remission from 1.7 to 8.4 years after transplantation, and the actuarial analysis shows a disease-free survival rate of 64%, with a plateau extending from 3.5 to 8.4 years. All lead normal lives.